Cowen’s Boris Peaker is not expecting a big driver can change investor sentiment on JNCE in the next 12-months after the firm exposed dismal ICONIC data.
Written by Dan Cohen In the wake of recently revealed abstracts from the 2018 ASCO meeting, Jounce therapeutics (NASDAQ:JNCE) stock price recently took …
Written by Danny Cohen and Scott Matusow The biotech “run-up” trade has always attracted a wide-array of traders looking to take advantage of …
